$34.50
0.030.09%
Dern. MÀJ: Oct 26, 3:30 PM
Indivior Pharmaceuticals (INDV) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
fiscal year (2026) a publié ses dernières prévisions le $1.29B - $1.36B pour Indivior Pharmaceuticals {{epsDirection}}. La société a prévu un chiffre d'affaires compris entre {{epsPriorRange}} et {{revenueDirection}} pour la période.
Par rapport aux prévisions précédentes, {{newestDate}} {{directionSummary}} ses prévisions de chiffre d'affaires ont été revues à la baisse, passant d'une fourchette précédente de undefined à undefined.
undefined a publié undefined mises à jour de ses recommandations entre undefined et undefined. undefined
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $0.92 | $0.66 | $0.66 | $0.40 |
| Actual | $1.15 | $0.96 | $0.82 | $0.72 |
| Surprise | +25.0% | +45.5% | +24.2% | +80.0% |
| Revenue | ||||
| Estimate | $306.8M | $272.0M | $305.5M | $261.1M |
| Actual | $343.0M | $317.0M | $358.0M | $314.0M |
| Surprise | +11.8% | +16.5% | +17.2% | +20.3% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E |
|---|---|---|---|
| Earnings Per Share (Non-GAAP) | |||
| Consensus | $1.08 | $1.19 | $1.00 |
| Revenue | |||
| Consensus | $328.8M | $336.6M | — |
| Trimestre Fiscal | Date de Déclaration | BPA Réel | BPA Estimé | Surprendre % |
|---|---|---|---|---|
| Q2 | Aug 3, 2026 | $1.15 | $0.92 | 25.0 % |
| Q1 | Apr 30, 2026 | $0.96 | $0.66 | 45.5 % |
| Q4 | Feb 26, 2026 | $0.82 | $0.66 | 24.2 % |
| Q3 | Oct 30, 2025 | $0.72 | $0.40 | 80.0 % |
| Trimestre Fiscal | Date de Déclaration | Revenu Réel | Revenu Estimé | Surprendre % |
|---|---|---|---|---|
| Q2 | Aug 3, 2026 | $343.00M | $306.84M | 11.8 % |
| Q1 | Apr 30, 2026 | $317.00M | $272.00M | 16.5 % |
| Q4 | Feb 26, 2026 | $358.00M | $305.46M | 17.2 % |
| Q3 | Oct 30, 2025 | $314.00M | $261.12M | 20.3 % |